How much revenue did Creo Medical Group generate this year?
Creo Medical Group has achieved a revenue of 39.96 M GBP this year.
Creo Medical Group Revenue 2024
Creo Medical Group Revenue
39.96 M GBP
Ticker
CREO.L
ISIN
GB00BZ1BLL44
WKN
A2DH40
In 2024, Creo Medical Group's sales reached 39.96 M GBP, a 29.73% difference from the 30.8 M GBP sales recorded in the previous year.
The Creo Medical Group Revenue history
| YEAR | REVENUE (undefined GBP) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 152.61 | 10,03 |
| 2028e | 127.91 | 11,96 |
| 2027e | 96.82 | 15,80 |
| 2026e | 70.7 | 21,64 |
| 2025e | 54.11 | 28,28 |
| 2024e | 39.96 | 38,29 |
| 2023 | 30.8 | 49,68 |
| 2022 | 27.17 | 48,30 |
| 2021 | 25.16 | 46,04 |
| 2020 | 9.43 | 42,79 |
| 2019 | 0.01 | 36,75 |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | - | - |
| 2013 | - | - |
Creo Medical Group Revenue, EBIT, Net Income GB00BZ1BLL44 · A2DH40
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Creo Medical Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Creo Medical Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Creo Medical Group’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Creo Medical Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Creo Medical Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Creo Medical Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Creo Medical Group’s growth potential.
Creo Medical Group Revenue, EBIT and net profit per share
| Date | Creo Medical Group Revenue | Creo Medical Group EBIT | Creo Medical Group Net Income |
|---|---|---|---|
| 2029e | 152.61 M undefined | 0 undefined | 0 undefined |
| 2028e | 127.91 M undefined | 0 undefined | 0 undefined |
| 2027e | 96.82 M undefined | 14.89 M undefined | 7.05 M undefined |
| 2026e | 70.7 M undefined | 4.04 M undefined | 5.19 M undefined |
| 2025e | 54.11 M undefined | -4.37 M undefined | -3.01 M undefined |
| 2024e | 39.96 M undefined | -15.79 M undefined | -13.72 M undefined |
| 2023 | 30.8 M undefined | -24.8 M undefined | -21.7 M undefined |
| 2022 | 27.17 M undefined | -30.76 M undefined | -26.94 M undefined |
| 2021 | 25.16 M undefined | -29.91 M undefined | -24.6 M undefined |
| 2020 | 9.43 M undefined | -23.48 M undefined | -20.32 M undefined |
| 2019 | 13,470 undefined | -18.88 M undefined | -15.91 M undefined |
| 2018 | 0 undefined | -17.66 M undefined | -14.81 M undefined |
| 2017 | 0 undefined | -8.9 M undefined | -7.77 M undefined |
| 2016 | 0 undefined | -1.87 M undefined | -1.61 M undefined |
| 2015 | 0 undefined | -3.8 M undefined | -3.33 M undefined |
| 2014 | 0 undefined | -2.88 M undefined | -2.38 M undefined |
| 2013 | 0 undefined | -1.95 M undefined | -1.7 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 0 GBP | -1.95 M GBP | -1.7 M GBP |
| 2014 | 0 GBP | -2.88 M GBP | -2.38 M GBP |
| 2015 | 0 GBP | -3.8 M GBP | -3.33 M GBP |
| 2016 | 0 GBP | -1.87 M GBP | -1.61 M GBP |
| 2017 | 0 GBP | -8.9 M GBP | -7.77 M GBP |
| 2018 | 0 GBP | -17.66 M GBP | -14.81 M GBP |
| 2019 | 13,470 GBP | -18.88 M GBP | -15.91 M GBP |
| 2020 | 9.43 M GBP | -23.48 M GBP | -20.32 M GBP |
| 2021 | 25.16 M GBP | -29.91 M GBP | -24.6 M GBP |
| 2022 | 27.17 M GBP | -30.76 M GBP | -26.94 M GBP |
| 2023 | 30.8 M GBP | -24.8 M GBP | -21.7 M GBP |
| 2024e | 39.96 M GBP | -15.79 M GBP | -13.72 M GBP |
| 2025e | 54.11 M GBP | -4.37 M GBP | -3.01 M GBP |
| 2026e | 70.7 M GBP | 4.04 M GBP | 5.19 M GBP |
| 2027e | 96.82 M GBP | 14.89 M GBP | 7.05 M GBP |
| 2028e | 127.91 M GBP | 0 GBP | 0 GBP |
| 2029e | 152.61 M GBP | 0 GBP | 0 GBP |
Creo Medical Group stock margins GB00BZ1BLL44 · A2DH40
The Creo Medical Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Creo Medical Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Creo Medical Group.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Creo Medical Group's sales revenue. A higher gross margin percentage indicates that the Creo Medical Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Creo Medical Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Creo Medical Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Creo Medical Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Creo Medical Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Creo Medical Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Creo Medical Group Margin History
| Creo Medical Group Gross margin | Creo Medical Group Profit margin | Creo Medical Group EBIT margin | Creo Medical Group Profit margin |
|---|---|---|---|
| 2029e | 49.68 % | 0 % | 0 % |
| 2028e | 49.68 % | 0 % | 0 % |
| 2027e | 49.68 % | 15.38 % | 7.28 % |
| 2026e | 49.68 % | 5.71 % | 7.34 % |
| 2025e | 49.68 % | -8.08 % | -5.57 % |
| 2024e | 49.68 % | -39.51 % | -34.34 % |
| 2023 | 49.68 % | -80.52 % | -70.45 % |
| 2022 | 48.3 % | -113.2 % | -99.14 % |
| 2021 | 46.04 % | -118.86 % | -97.75 % |
| 2020 | 42.79 % | -249.07 % | -215.46 % |
| 2019 | 36.75 % | -140,129.03 % | -118,122.86 % |
| 2018 | 49.68 % | 0 % | 0 % |
| 2017 | 49.68 % | 0 % | 0 % |
| 2016 | 49.68 % | 0 % | 0 % |
| 2015 | 49.68 % | 0 % | 0 % |
| 2014 | 49.68 % | 0 % | 0 % |
| 2013 | 49.68 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 49.68 % | 0 % | 0 % |
| 2014 | 49.68 % | 0 % | 0 % |
| 2015 | 49.68 % | 0 % | 0 % |
| 2016 | 49.68 % | 0 % | 0 % |
| 2017 | 49.68 % | 0 % | 0 % |
| 2018 | 49.68 % | 0 % | 0 % |
| 2019 | 36.75 % | -140,129.03 % | -118,122.86 % |
| 2020 | 42.79 % | -249.07 % | -215.46 % |
| 2021 | 46.04 % | -118.86 % | -97.75 % |
| 2022 | 48.3 % | -113.2 % | -99.14 % |
| 2023 | 49.68 % | -80.52 % | -70.45 % |
| 2024e | 49.68 % | -39.51 % | -34.34 % |
| 2025e | 49.68 % | -8.08 % | -5.57 % |
| 2026e | 49.68 % | 5.71 % | 7.34 % |
| 2027e | 49.68 % | 15.38 % | 7.28 % |
| 2028e | 49.68 % | 0 % | 0 % |
| 2029e | 49.68 % | 0 % | 0 % |
Creo Medical Group Aktienanalyse
What does Creo Medical Group do?
Creo Medical Group PLC is a British medical technology company that was founded in 2003 and is based in Chepstow, Wales. The company specializes in the development and marketing of innovative medical devices. Creo Medical aims to improve the lives of healthcare professionals and patients by providing them with state-of-the-art technology. The company's business model focuses on research, development, and sales of innovative medical devices. Their goal is to provide doctors with the most advanced technology to facilitate their work. Creo Medical offers a wide range of devices for endoscopic surgery. They follow an asset-light model, outsourcing production to save costs and increase efficiency. Creo Medical was founded in 2003 by a team of professionals consisting of doctors and engineers. Their objective was to promote the development of cutting-edge technology for the medical industry and improve the treatment of patients worldwide. The company quickly gained momentum and received its first patent in 2014. Their product range includes endoscopes and electrosurgical devices for endoscopic surgery. Endoscopes are used to visualize the internal surfaces of the body through a flexible tube inserted through a small incision. This type of technology is used in surgery, particularly in gastrointestinal and gynecological areas. Electrosurgical devices are used in heart surgery and to prevent bleeding during operations. Creo Medical operates in various sectors where their products are utilized: 1. Gastroenterology: focusing on the diagnosis and treatment of digestive tract diseases. 2. Laparoscopic surgery: a surgical technique that uses a few small incisions to introduce surgical instruments into the body. 3. Gynecology: dealing with the diagnosis and treatment of diseases in the female reproductive system. 4. Urology: involving the treatment of diseases in the urinary tract and male reproductive system. Creo Medical serves multiple markets and recently announced the acquisition of Albyn Medical, a leading British manufacturer and distributor of medical devices. The company reported a 68% increase in revenue to £8.8 million in 2020, attributing the growth to growing demand for laparoscopic and gastroenterological products. Creo Medical's stock was listed on London's AIM in 2018. In conclusion, Creo Medical is a British medical technology company specializing in the development, manufacturing, and marketing of medical devices used in various medical fields. Their advanced technologies contribute to breakthroughs in surgery, making procedures more precise and gentle. Creo Medical has become a significant player in the British and international medical industry and will continue to play an important role in this sector. Creo Medical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Creo Medical Group's Sales Figures
The sales figures of Creo Medical Group originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Creo Medical Group’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Creo Medical Group's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Creo Medical Group’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Creo Medical Group stock
How much was the turnover of the company Creo Medical Group compared to the previous year?
The revenue of Creo Medical Group has increased by 29.73% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Creo Medical Group?
The revenue of Creo Medical Group is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Creo Medical Group measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Creo Medical Group so important for investors?
The revenue of Creo Medical Group is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Creo Medical Group pay?
Over the past 12 months, Creo Medical Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Creo Medical Group is expected to pay a dividend of 0 GBP.
What is the dividend yield of Creo Medical Group?
The current dividend yield of Creo Medical Group is .
When does Creo Medical Group pay dividends?
Creo Medical Group pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Creo Medical Group?
Creo Medical Group paid dividends every year for the past 0 years.
What is the dividend of Creo Medical Group?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Creo Medical Group located?
Creo Medical Group is assigned to the 'Health' sector.
Wann musste ich die Aktien von Creo Medical Group kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Creo Medical Group from 9/30/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.
When did Creo Medical Group pay the last dividend?
The last dividend was paid out on 9/30/2024.
What was the dividend of Creo Medical Group in the year 2023?
In the year 2023, Creo Medical Group distributed 0 GBP as dividends.
In which currency does Creo Medical Group pay out the dividend?
The dividends of Creo Medical Group are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Creo Medical Group
Our stock analysis for Creo Medical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Creo Medical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Creo Medical Group Revenue
- Creo Medical Group Net Income
- Creo Medical Group P/E
- Creo Medical Group P/S
- Creo Medical Group EBIT
- Creo Medical Group Dividend
- Creo Medical Group Stocks
- Creo Medical Group Market capitalization
- Creo Medical Group Debt
- Creo Medical Group Liabilities
- Creo Medical Group Equity
- Creo Medical Group AAQS
- Creo Medical Group Employees
- Creo Medical Group ROE
- Creo Medical Group ROA
- Creo Medical Group ROCE
